Sinocare announced that its product, the blood glucose and ketone test strip, has passed the special review for Class II innovative medical devices in Hunan Province. The product can quantitatively detect glucose and beta-hydroxybutyrate concentrations in fresh capillary whole blood and venous whole blood, with a single strip capable of simultaneously testing both blood glucose and ketone levels. In addition, the company has made changes to the registration certificates for several medical devices, including blood lipid control solutions and blood lipid test strips, involving product technical requirements, instructions, and packaging specifications, in order to optimize product performance and specifications. In the first quarter of 2026, Sinocare achieved revenue of 1.239 billion yuan and net profit attributable to the parent company of 97.69 million yuan.
Sinocare IncProduct passed special review for innovative medical devices, enabling dual-test capability.